Since the JAK1-STAT pathway plays a critical role in psoriasis and DM, upadacitinib, a highly selective JAK1 inhibitor, may be an effective and safe option for treating refractory concomitant skin autoimmune diseases with JAK1- STAT pathway activation [48]. Here, SOAT1 is linked to dermatomyositis.